Clinical Trial Update: FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for FORWARD Optune with adjuvant temozolomide in Grade II/III astrocytoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Grade Ii
• Astrocytoma Grade Iii

Drugs mentioned

• FORWARD Optune
• Temozolomide (Temozolomide)

Snippet

Sponsor: University of Florida | Conditions: Astrocytoma, Grade II, Astrocytoma, Grade III | Phase 2 | Status: TERMINATED | Results posted: 2021-09-23